Skip to main content
CRNX
NASDAQ Life Sciences

Crinetics 在巴西提交 Palsonify 上市申请，扩大了针对肢端肥大症治疗的全球范围

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$36.31
Mkt Cap
$3.802B
52W Low
$24.1
52W High
$57.99
Market data snapshot near publication time

summarizeSummary

Crinetics 制药公司宣布向巴西国家卫生监督局（ANVISA）提交了 Palsonify（paltusotine）的上市申请，以治疗肢端肥大症。这一举动是在该产品最近在美国获得 FDA 批准和在欧洲获得积极的监管意见之后，标志着公司全球商业化战略的重要一步。该申请得到了全面临床数据的支持，包括两个积极的 3 期试验。这一扩张进入巴西市场是一个积极的发展，表明 Palsonify 持续增长的潜力和更广泛的市场准入，而 Palsonify 自 2025 年第四季度开始产生收入。交易者现在将关注巴西的监管审查过程和潜在的批准更新。

在该公告发布时，CRNX的交易价格为$36.31，交易所为NASDAQ，所属行业为Life Sciences，市值约为$38亿。 52周交易区间为$24.10至$57.99。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CRNX - Latest Insights

CRNX
Apr 27, 2026, 5:13 PM EDT
Source: GlobeNewswire
Importance Score:
9
Crinetics' PALSONIFY Wins EU Approval for Acromegaly, Paving Way for European Launch
Sentiment: Positive
View Wiseek Article
CRNX
Mar 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Crinetics Submits Palsonify MAA in Brazil, Expanding Global Reach for Acromegaly Treatment
Sentiment: Positive
View Wiseek Article
CRNX
Mar 23, 2026, 9:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Crinetics Pharmaceuticals CDOO Resigns to Pursue New Opportunity
Sentiment: Neutral
View Wiseek Article
CRNX
Feb 26, 2026, 4:25 PM EST
Filing Type: 10-K
Importance Score:
8
Crinetics Pharmaceuticals Reports First Product Revenue, Positive EU Regulatory Opinion for PALSONIFY, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
CRNX
Feb 26, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Reports First PALSONIFY Product Revenue of $5.4M in Q4 2025, Strong Launch, Positive EU Opinion, and Pipeline Progress
Sentiment: Positive
View Wiseek Article
CRNX
Jan 13, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Reports Early PALSONIFY Revenue, Strong Cash, and Advances Multiple Programs to Phase 3
Sentiment: Positive
View Wiseek Article
CRNX
Jan 07, 2026, 4:39 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Pharmaceuticals Prices $350M Public Offering at Discount to Market, Securing Significant Capital
Sentiment: Neutral
View Wiseek Article
CRNX
Jan 07, 2026, 4:03 PM EST
Filing Type: 424B5
Importance Score:
8
Crinetics Pharmaceuticals Announces $350M Public Offering at Discounted Price
Sentiment: Negative
View Wiseek Article
CRNX
Jan 05, 2026, 4:20 PM EST
Filing Type: 424B5
Importance Score:
8
Crinetics Pharmaceuticals Announces $350M Common Stock Offering to Fund Commercial Launch and R&D
Sentiment: Negative
View Wiseek Article
CRNX
Jan 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Crinetics Reports Strong PALSONIFY Launch & Positive Phase 2 Atumelnant Data for CAH
Sentiment: Positive
View Wiseek Article